regulatory T cell
regulatory T cell
Overview
Regulatory T cells, often abbreviated as Tregs, are a specialized subset of CD4+ T lymphocytes that maintain immune tolerance and limit excessive immune activation. They are defined by suppressive function and lineage programs centered on FOXP3, which is widely regarded as an essential transcription factor for Treg development and activity. By restraining effector T-cell responses, Tregs help prevent autoimmunity and tissue damage, but they can also suppress beneficial antitumor immunity when enriched in tumors or other immunosuppressive settings.
Biologically, Tregs act through multiple mechanisms, including inhibitory cytokines, cell-contact-dependent suppression, metabolic competition, and modulation of antigen-presenting and myeloid cells. In recent biomedical research, they are frequently discussed in relation to the tumor microenvironment, immune checkpoint therapy, intestinal tolerance, chronic inflammation, and graft-versus-host disease. Because of this dual role, Tregs are both a therapeutic target for cancer immunotherapy and a therapeutic product in autoimmune disease and transplantation.
Focus of Latest Publications
Recent studies have examined regulatory T cells in a wide range of disease contexts, with a strong emphasis on cancer immunology and immune suppression. In advanced non-small cell lung cancer, elevated frequencies of regulatory T cells near CD3 T cells at baseline were associated with improved outcome to pembrolizumab plus gemcitabine in a phase I/II study, suggesting that spatial immune context may influence response to anti-PD-1 treatment. In other tumor studies, Treg abundance or infiltration was repeatedly linked to immunosuppressive microenvironments and resistance to therapy, including in ovarian cancer, bladder cancer, lung adenocarcinoma, cervical cancer, lymphoma, pancreatic cancer, renal carcinoma, and brain metastases of melanoma.
Several publications specifically described interventions that reduced Treg levels or function to enhance antitumor immunity. An aminated fullerene-based nanoplatform decreased regulatory T-cell levels while increasing T-cell infiltration and activation, consistent with enhanced antitumor immunity. A polymannose-guided photodynamic immunotherapy platform increased CD8+ cytotoxic T-cell infiltration and reduced Treg proportions in tumor tissue. Similarly, glycerol-mediated nose-to-brain codelivery of anti-IL-17 and anti-CD73 antibodies promoted CD8+ T-cell activation and residency, reduced Treg infiltration, and produced a strong antitumor effect in melanoma brain metastases. In another study, a “one-two punch” strategy combining immunometabolic reprogramming with checkpoint blockade was reported to support ipilimumab-mediated depletion of regulatory T cells, thereby enabling robust activation of primed CD8+ T cells.
Other cancer-focused studies emphasized mechanisms that promote Treg differentiation, maintenance, or suppressive function. Tumor-derived exosomes were reported to facilitate immune evasion by impairing cytotoxic T lymphocytes, promoting Treg differentiation, and polarizing macrophages toward an M2 phenotype. SAICAR was described as driving T regulatory cell differentiation and FOXP3 maintenance, contributing to immunotherapy resistance. In cervical cancer, elevated IGSF3 expression on tumor cells was identified as a driver of enhanced Treg infiltration and function through TNFR2 on Tregs. In renal carcinoma, VISTA was highlighted as an inhibitory immune checkpoint enriched in myeloid cells and regulatory T cells, underscoring its role as a barrier to effective antitumor immunity. Additional studies linked Treg enrichment with aging-related immunosuppression in ovarian tumors, metabolic checkpoint regulation in anti-PD-1 resistance, and suppressive niches enriched in Tregs and myofibroblastic cancer-associated fibroblasts.
Beyond oncology, Tregs were also studied in immune tolerance and inflammatory disease. A JEM study showed that intestinal regulatory T cells recognizing dietary- or microbiota-derived antigens express RORγt and are essential for immune tolerance in the intestine, while B7 costimulation was reported to antagonize these RORγt+ Treg cells. Spatial transcriptomics in inflammatory bowel disease identified regulatory T cell-associated biology in both disease subtypes, reinforcing their relevance in mucosal immune homeostasis. In bovine coronavirus-infected calf jejunum, a deoxycholic acid deficiency was linked to Th17/Treg imbalance, with suppression of Treg differentiation proposed as part of the pathology. In sepsis and acute pancreatitis, regulatory T cells were described as modulators of immune responses, and serum CCL1 was evaluated as a discriminator of infectious versus sterile systemic inflammation.
Tregs were also central in transplantation and autoimmune research. Impaired Treg recovery in chronic graft-versus-host disease motivated clinical studies aimed at increasing peripheral Treg numbers, including phase 1/2 trials of donor regulatory T cells. Preclinical work on engineered regulatory T cells for IPEX and other autoimmune disorders highlighted FOXP3-dependent lineage commitment and function, supporting the therapeutic use of Treg infusions. Related immunomodulatory studies included belatacept and calcineurin inhibitor contexts, where T-cell regulation is clinically relevant, as well as freshly isolated donor-derived Treg infusions and CliniMACS-based cell processing.
Across these studies, Tregs were consistently positioned as a key determinant of immune balance: protective in tolerance and autoimmunity, but often detrimental in cancer by suppressing cytotoxic T-cell activity and supporting immune escape. Their abundance, phenotype, and spatial organization were repeatedly associated with clinical outcome, immune checkpoint responsiveness, and the broader composition of the tumor microenvironment, including macrophages, dendritic cells, and CD8+ T cells.